Clinical trial NCT06844708: CMTS0929 for Inflammatory Bowel Disease
Official title: CMTS0929 for Inflammatory Bowel Disease: a Prospective, Open-label, Single-arm Clinical Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: EARLY_PHASE1
Conditions: Inflammatory Bowel Disease (IBD)
Keywords: inflammatory bowel disease
CMTS0929
efficacy
safety
Lead sponsor: The Second Hospital of Nanjing Medical University
Sponsor class: OTHER
First posted: 2025-02-25
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Eligible subjects will receive treatment with CMTS0929. They will be administered one unit of the liquid via colonic transendoscopic enteral tube (cTET) for three consecutive days.
Primary purpose: TREATMENT

Brief summary: This is a prospective, open-label, single-arm study to explore the safety and the efficacy of China Microbiota Transplantation System 0929 (CMTS0929) for patients with inflammatory bowel disease (IBD).

Detailed description: At least 12 subjects who meet all the inclusion criteria but do not meet any exclusion criteria will be enrolled in this study. Data of demographic characteristics and clinical data will be collected. After treatment, they will enter the follow-up period for safety and efficacy evaluation.

Eligibility criteria: Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to enter the study:

1. Patients diagnosed with inflammatory bowel disease (IBD) based on typical clinical symptoms, endoscopic findings, and histological criteria.
2. Aged between 18 and 75 years old, regardless of gender.
3. No history of using antibiotics, prebiotics, or probiotics within at least the past month.
4. Patients who can fully understand the content of the informed consent form for this trial and voluntarily sign the written informed consent.
5. Patients willing to undergo subsequent follow - up and comply with other requirements of the protocol.

Exclusion Criteria:

Subjects meeting any of the following exclusion criteria must be excluded from the study:

1. Women who are pregnant or plan to become pregnant during the trial.
2. Patients who have any doubts about this technology or have a history of other risks.
3. Patients in the terminal stage of the disease or who may die during the study.
4. Patients with a history of antibiotic use within three months before transplantation or who have participated in other clinical trials.
5. Patients who have participated in any other microbiota - based therapies before enrollment.
6. Patients with positive antibodies for hepatitis B, tuberculosis, syphilis, or HIV, or those in the acute phase of any infectious disease.
7. Patients with cardiac function at grade III or higher, elevated transaminases more than twice the upper limit of the normal range, or renal insufficiency (glomerular filtration rate (GFR) less than 60 ml/min).
8. Patients with a fever of over 38 °C or clinically obvious active infections that may affect this trial.
9. Patients with severe anemia (hemoglobin \< 60 g/L), granulocytopenia (absolute neutrophil count \< 1.5×10⁹/L), or prolonged prothrombin time (PT) by more than 1.5 seconds.
10. Patients with obvious cardiovascular and cerebrovascular abnormalities (such as tachycardia or uncontrolled atrial fibrillation, acute coronary syndrome, stroke, or recurrent transient ischemic attacks (TIAs)); a history of arrhythmia (multifocal ventricular premature beats, bigeminy, trigeminy, congenital long QT syndrome), or patients with heart diseases that, in the judgment of the researcher, increase the risk of ventricular arrhythmia.
11. Situations identified by the researcher during the trial that may affect the patient's compliance and/or the completion of trial - related procedures, or clinical contraindications related to the pre - trial.
12. Patients who have undergone abdominal organ surgery within three months before treatment, patients less than 6 weeks after major organ surgery, or patients with poor wound healing after surgery.
13. Patients with gastrointestinal obstructive diseases, tumors, or hepatic or renal insufficiency.
14. Pregnant or lactating women, or women with the intention of becoming pregnant.
15. Patients suspected or confirmed to be drug users, or those with a history of immunodeficiency (such as positive HIV antibodies or currently receiving immunosuppressive therapy).
16. Patients with known major active infections, or those with major disorders in blood, renal, metabolic, gastrointestinal, or endocrine functions as judged by the researcher.
17. Other situations deemed unsuitable for enrollment by the researcher.

Primary outcomes:
measure: The efficacy of China Microbiota Transplantation System 0929 (CMTS0929)
timeFrame: Four-week
measure: The efficacy of China Microbiota Transplantation System 0929 (CMTS0929)
timeFrame: Four-week
Secondary outcomes:
measure: The changes in endoscopic score
timeFrame: Three-month, Six-month
measure: The change in hematochezia compared with baseline
timeFrame: One-week, Four-week, Twelve-week, Six-month
measure: The change in frequency of defecation compared with baseline
timeFrame: One-week, Four-week, Twelve-week, Six-month
measure: The change in abdominal pain compared with baseline
timeFrame: One-week, Four-week, Twelve-week, Six-month
measure: The incidence of IBD-related complications
timeFrame: One-week, Four-week, Twelve-week, Six-month
measure: The rate of surgical intervention
timeFrame: Six-month
measure: The safety of CMTS0929
timeFrame: Immediately, One-week, Two-week, Four-week, Three-month, Six-month
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
state: Jiangsu
Study officials:
affiliation: The Second Hospital of Nanjing Medical University
name: Faming Zhang, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wortelboer K, de Jonge PA, Scheithauer TPM, Attaye I, Kemper EM, Nieuwdorp M, Herrema H. Phage-microbe dynamics after sterile faecal filtrate transplantation in individuals with metabolic syndrome: a double-blind, randomised, placebo-controlled clinical trial assessing efficacy and safety. Nat Commun. 2023 Sep 12;14(1):5600. doi: 10.1038/s41467-023-41329-z.
citation: Shaukat A, Shyne M, Mandel JS, Snover D, Church TR. Colonoscopy With Polypectomy Reduces Long-Term Incidence of Colorectal Cancer in Both Men and Women: Extended Results From the Minnesota Colon Cancer Control Study. Gastroenterology. 2021 Mar;160(4):1397-1399.e3. doi: 10.1053/j.gastro.2020.11.014. Epub 2020 Nov 17. No abstract available.
citation: Zhang F, Cui B, He X, Nie Y, Wu K, Fan D; FMT-standardization Study Group. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018 May;9(5):462-473. doi: 10.1007/s13238-018-0541-8. Epub 2018 Apr 24.
citation: Piovani D, Hassan C, Repici A, Rimassa L, Carlo-Stella C, Nikolopoulos GK, Riboli E, Bonovas S. Risk of Cancer in Inflammatory Bowel Diseases: Umbrella Review and Reanalysis of Meta-analyses. Gastroenterology. 2022 Sep;163(3):671-684. doi: 10.1053/j.gastro.2022.05.038. Epub 2022 May 26.
citation: Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017 Apr 29;389(10080):1756-1770. doi: 10.1016/S0140-6736(16)32126-2. Epub 2016 Dec 1.
citation: Hodson R. Inflammatory bowel disease. Nature. 2016 Dec 21;540(7634):S97. doi: 10.1038/540S97a. No abstract available.